Bent Raungaard

Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial

Thomas Engstrøm, Henning Kelbæk, Steffen Helqvist et al. · The Lancet · 2015 · 966 citations

Medicine, Cardiology, Internal Medicine +16

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial

Derek J. Hausenloy, Rajesh Kharbanda, Ulla Møller et al. · The Lancet · 2019 · 324 citations · Full text

Medicine, Cardiology, Clinical Cardiology +16

Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial

Henning Kelbæk, Dan Eik Høfsten, Lars Køber et al. · The Lancet · 2016 · 206 citations

Medicine, Cardiology, Clinical Cardiology +11

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17